News
April 15, 2008
Advaxis Discloses Clinical Results of the First Ever Live Listeria Monocytogenes Trial
CSO John Rothman, PhD, Speaks On Flagship Drug Candidate, Lovaxin C, At The American Association For Cancer Research In San Diego, CA
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Inc. (OTCBB: ADXS, http://www.advaxis.com), a developmental biotechnology company, presented landmark clinical trial results of its flagship drug candidate, Lovaxin C, at the American Associate for Cancer Research (“AACR”) this past Sunday, April 13th, in San Diego, CA.
Dr. John Rothman, Advaxis’ chief science officer, addressed the following elements in his presentation:
* The finding: Lovaxin-C, given to end-stage cancer patients in this trial, was safe
* The response rate associated with Lovaxin C in this trial
* The survival rate of patients treated with Lovaxin C in this trial
“This is a landmark event for Advaxis and the entire cancer space,” said Advaxis Chairman and CEO Thomas Moore. “The trial was the first ever of a live Listeria monocytogenes bacterium. We believe our accomplishments and future progress can help establish a new paradigm in the war against cancer.”
For more information about the event, please e-mail your inquiries to: aacr@investorrelationsgroup.com or Michaela Heller at michaela@investorrelationsgroup.com.
About The American Association For Cancer Research
The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attracts the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.
The AACR:
* Publishes six peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research.
* Publishes CR, a magazine for cancer survivors, patient advocates, their families, physicians and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.
* Convenes topical scientific conferences and an annual meeting that draws more than 17,000 participants from the cancer research community.
* Offers workshops, fellowships and grants for early-career investigators and investigators-in-training.
* Collaborates with cancer survivors, raises public awareness of the progress in and cause for hope in cancer research and advocates for strong federal research funding.
For further information, please visit www.aacr.org.
About Advaxis, Inc.
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (“Lm”) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system’s cancer-fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely.
Advaxis’ lead Lm vaccine candidate – Lovaxin C – targets cervical and head and neck cancers. Current Lm vaccines in development target prostate, breast, ovarian and lung cancers. Advaxis has completed a Phase I/II clinical trial. The Lm platform will also have applications in the fields of infectious disease and autoimmune disorders.
For further information on the Company, please visit: http://www.advaxis.com.
About Lovaxin C Vaccine
Advaxis’ Listeria technology platform uses modified Listeria monocytogenes to deliver a proprietary tumor-specific antigen fusion protein. Lm, as bioengineered to be attenuated and to secrete Advaxis’ proprietary fusion protein, has the ability to generate a robust immune response and produce an unusually strong and effective multi-level therapeutic immune response to existing cancers and other diseases.
Advaxis’ Lm-based technology is based on Dr. Yvonne Paterson’s decade worth of work in her laboratory at the University of Pennsylvania. The Company’s proprietary antigen fusion protein technology, also suppresses regulatory T cells that inhibit many vaccines in the creation of activated tumor-killing cells.
Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting a human papilloma virus (“HPV”) infection, which is the most prevalent sexually transmitted disease in the US. Current prophylactic products on the market are ineffective in treating HPV-infected women.
For further information on Lovaxin C, please visit: http://www.advaxis.com/lc.htm
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Company Contact:
Advaxis, Inc.
Thomas A. Moore
732-545-1590
moore@advaxis.com